CASC
ACAD icon

Coppell Advisory Solutions Corp’s Acadia Pharmaceuticals ACAD Stock Holding History

Coppell Advisory Solutions Corp’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-600
Closed -$9.55K – 207
2022
Q4 		$9.55K Buy
+600
New +$9.38K ﹤0.01% 620

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Coppell Advisory Solutions Corp's ACAD Position: Q1 2023 in Review

Coppell Advisory Solutions Corp sold out of Acadia Pharmaceuticals (ACAD) in Q1 2023, closing a stake of 600 shares — an estimated $9.55K sold.

Coppell Advisory Solutions Corp first reported a position in ACAD in Q4 2022 and held it in 1 quarter. The position peaked at $9.55K in Q4 2022. 233 funds tracked by Wall St. Rank hold ACAD as of Q1 2023.

  • Coppell Advisory Solutions Corp reported no remaining Acadia Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Coppell Advisory Solutions Corp sold 600 Acadia Pharmaceuticals shares in Q1 2023, an estimated $9.55K.
  • Coppell Advisory Solutions Corp first reported a position in Acadia Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Coppell Advisory Solutions Corp's Acadia Pharmaceuticals position peaked at $9.55K in Q4 2022.
  • 233 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2023.

Based on Coppell Advisory Solutions Corp's 13F filing for Q1 2023, filed 10 May 2023.